The Trump administration abruptly ended a $258 million HIV vaccine research program at Duke University and Scripps Research Institute. The program, involving numerous collaborators, had broad applications beyond HIV, including COVID-19 treatments and other therapies. NIH leadership cited a review as the reason for termination, delivering the news Friday to program leaders. This decision halts significant progress in HIV vaccine development.

Prepared by Olivia Bennett and reviewed by editorial team.